US-based Momenta Pharmaceuticals has revised its regulatory strategy in the US for its anti-FcRn antibody M923, which the company has proposed as a biosimilar to Humira, it was reported on Tuesday.
The company had indicated earlier that it planned to file a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in the fourth quarter of 2018.
With the recent Abbvie agreement, Momenta will be able to commercialise M923 in the United States, pending regulatory approval, as early as November 20, 2023. The company has decided to delay the filing of the BLA, which is likely to reduce programme costs in 2019 without delaying M923's potential US market entry.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval